By Dr Mark William Donoghoe

Journal articles

Ting R; Keech A; Drury P; Donoghoe M; Hedley J; Jenkins AJ; Davis T; Lehto S; Celermajer DS; Simes J; Kushwin R; Stanton K; Suranyi MG, 2012, 'Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment', Diabetes Care, 35, pp. 218 - 225, http://dx.doi.org/10.2337/dc11-1109

Scott R; Donoghoe M; Watts GF; O'Brien R; Pardy C; Taskinen MR; Davis TME; Colman PG; Manning P; Fulcher G; Keech AC, 2011, 'Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the field randomised trial', Cardiovascular Diabetology, 10, http://dx.doi.org/10.1186/1475-2840-10-102

Sullivan D; Forder P; Simes J; Whiting M; Kritharides L; Merrifield A; Donoghoe M; Colman PG; Graham N; Haapamäki H; Keech A, 2011, 'Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study', Diabetes Research and Clinical Practice, 94, pp. 284 - 290, http://dx.doi.org/10.1016/j.diabres.2011.07.028

Joly F; Ray-Coquard I; Fabbro M; Donoghoe M; Boman K; Sugimoto A; Vaughan M; Reinthaller A; Vergote I; Ferrandina G; Dell'Anna T; Huober J; Pujade-Lauraine E, 2011, 'Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: Analysis from the GCIG CALYPSO relapsing ovarian cancer trial', Gynecologic Oncology, 122, pp. 226 - 232, http://dx.doi.org/10.1016/j.ygyno.2011.04.019

Davis TME; Ting R; Best JD; Donoghoe MW; Drury PL; Sullivan DR; Jenkins AJ; O'Connell RL; Whiting MJ; Glasziou PP; Simes RJ; Kesäniemi YA; Gebski VJ; Scott RS; Keech AC, 2011, 'Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study', Diabetologia, 54, pp. 280 - 290, http://dx.doi.org/10.1007/s00125-010-1951-1

Ting R; Davis T; Drury P; Donoghoe M; Rajamani K; Best J; Kesaniemi Y; Keech A, 2011, 'Cardiovascular Risk, Renal Status and Fenofibrate Safety in the FIELD Study', Heart, Lung and Circulation, 20, pp. S202 - S202, http://dx.doi.org/10.1016/j.hlc.2011.05.497

Donoghoe MW; Gebski V, 2011, 'Impact of the censoring distribution on time-to-event problems in the presence of competing risks', Trials, 12, http://dx.doi.org/10.1186/1745-6215-12-s1-a140

Ting R-D; Davis TME; Drury PL; Donoghoe M; Rajamani K; Best JD; Kesaniemi YA; Keech AC, 2010, 'CARDIOVASCULAR AND RENAL SAFETY OF FENOFIBRATE IN THE FIELD STUDY', ATHEROSCLEROSIS SUPPLEMENTS, 11, pp. 219 - 219, http://dx.doi.org/10.1016/S1567-5688(10)71044-8

Rajamani K; Donoghoe M; Li L; Ting R-D; Colman P; Scott R; Laakso M; Keech A, 2010, 'FENOFIBRATE REDUCES PERIPHERAL NEUROPATHY IN TYPE 2 DIABETES: THE FENOFIBRATE INTERVENTION AND EVENT LOWERING IN DIABETES (FIELD) STUDY', ATHEROSCLEROSIS SUPPLEMENTS, 11, pp. 219 - 220, http://dx.doi.org/10.1016/S1567-5688(10)71046-1

Sullivan D; Donoghoe M; Simes J; George J; Keech T, 2009, 'Abstract: P496 LONG-TERM FENOFIBRATE USE IS ASSOCIATED WITH REDUCED PREVALENCE OF LIVER ENZYME ELEVATION IN THE FIELD STUDY', Atherosclerosis Supplements, 10, pp. e809 - e809, http://dx.doi.org/10.1016/s1567-5688(09)70791-3

Back to profile page